Vanda Pharmaceuticals (VNDA) Cost of Revenue (2010 - 2026)

Vanda Pharmaceuticals' Cost of Revenue history runs 14 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 10.28% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $12.7 million (up 11.29% YoY), while the FY2025 annual figure was $13.0 million, up 15.29% from the prior year.
• Cost of Revenue came in at $3.2 million for Q1 2026 at Vanda Pharmaceuticals, down from $3.8 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $6.3 million in Q3 2022 to a low of $2.6 million in Q3 2024.
• A 5-year average of $3.9 million and a median of $3.5 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue slumped 51.53% in 2023 and soared 47.99% in 2025, its largest moves.
• Vanda Pharmaceuticals' Cost of Revenue stood at $6.2 million in 2022, then sank by 44.53% to $3.5 million in 2023, then retreated by 25.14% to $2.6 million in 2024, then jumped by 47.99% to $3.8 million in 2025, then fell by 17.58% to $3.2 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.2 million, $3.8 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison